Immunic (NASDAQ:IMUX - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Friday.
Separately, Brookline Capital Management restated a "buy" rating and set a $10.00 price target on shares of Immunic in a research note on Friday, April 5th.
Get Our Latest Stock Analysis on IMUX
Immunic Price Performance
Immunic stock traded down $0.09 during trading hours on Friday, hitting $1.18. The company had a trading volume of 365,394 shares, compared to its average volume of 876,208. The firm has a market capitalization of $106.12 million, a P/E ratio of -0.56 and a beta of 2.07. The firm's fifty day moving average is $1.33 and its 200-day moving average is $1.27. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $3.11.
Immunic (NASDAQ:IMUX - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.03. Analysts anticipate that Immunic will post -0.99 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. LPL Financial LLC acquired a new position in shares of Immunic during the 2nd quarter worth $28,000. MetLife Investment Management LLC bought a new stake in shares of Immunic during the 1st quarter worth $134,000. JPMorgan Chase & Co. boosted its holdings in shares of Immunic by 21.2% during the 1st quarter. JPMorgan Chase & Co. now owns 13,649 shares of the company's stock worth $154,000 after buying an additional 2,387 shares during the period. Two Sigma Securities LLC bought a new stake in shares of Immunic during the 2nd quarter worth $36,000. Finally, Wolverine Trading LLC bought a new stake in Immunic in the 2nd quarter valued at $42,000. Institutional investors and hedge funds own 51.82% of the company's stock.
About Immunic
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
